FACS-Based Functional Protein Screening via Microfluidic Co-encapsulation of Yeast Secretor and Mammalian Reporter Cells by Yanakieva, Desislava et al.
1Scientific RepoRtS |        (2020) 10:10182  | https://doi.org/10.1038/s41598-020-66927-5
www.nature.com/scientificreports
fAcS-Based functional protein 
Screening via Microfluidic Co-
encapsulation of Yeast Secretor and 
Mammalian Reporter cells
Desislava Yanakieva1, Adrian elter1,4, Jens Bratsch2, Karlheinz friedrich2, Stefan Becker3 & 
Harald Kolmar1,4 ✉
in this study, we present a straightforward approach for functional cell-based screening by co-
encapsulation of secretor yeast cells and reporter mammalian cells in millions of individual agarose-
containing microdroplets. our system is compatible with ultra-high-throughput selection utilizing 
standard fluorescence-activated cell sorters (FACS) without need of extensive adaptation and 
optimization. In a model study we co-encapsulated murine interleukin 3 (mIL-3)-secreting S. cerevisiae 
cells with murine Ba/F3 reporter cells, which express green fluorescent protein (GFP) upon stimulation 
with mIL-3, and could observe specific and robust induction of fluorescence signal compared to a 
control with yeast cells secreting a non-functional mIL-3 mutant. We demonstrate the successful 
enrichment of activating mIL-3 wt-secreting yeast cells from a 1:10,000 dilution in cells expressing the 
inactive cytokine variant by two consecutive cycles of co-encapsulation and fAcS. this indicates the 
suitability of the presented strategy for functional screening of high-diversity yeast-based libraries and 
demonstrates its potential for the efficient isolation of clones secreting bioactive recombinant proteins.
The importance of biopharmaceuticals (biologics) in medicine is increasing at a fast pace and the biologics market 
is predicted to reach nearly 400 billion USD/year by 20251. Frequently applied biologics comprise substances such 
as cytokines, monoclonal antibodies, hormones, soluble receptors, recombinant DNAs, enzymes, and synthetic 
vaccines.
While biologics in targeted therapies often demonstrate remarkable safety and specificity, especially in case of 
autoimmune diseases2 and cancer3, the discovery of novel molecules and the necessary functional validation still 
represent a bottleneck in the development of novel biopharmaceuticals. To overcome these shortcomings, power-
ful display technologies such as phage display4 and yeast surface display5 have been developed which allow for the 
isolation of specific high-affinity molecules and respective genes from complex variant libraries. However, iden-
tified binders frequently show poor physiological activity in a biological context. Thus, extensive secondary func-
tional screens are necessary for identification of hit molecules with the desired functional activity. Furthermore, 
those screens require elaborate subcloning of the surface-displayed hits into soluble expression formats and out-
coming clones frequently demand further optimization of physicochemical and pharmacokinetic properties6.
Consequently, implementing functional assays and phenotypic screens in an earlier selection phase appears 
highly beneficial for the discovery of new potent biologic drugs or even first-in-class medicines with novel molec-
ular mechanisms of action7. In this context, a major limitation is represented by the relatively low throughput 
of classical phenotypic screens, falling far behind the performance of high-diversity library-based approaches 
resting on affinity-driven selection protocols8.
Complex protein-protein interactions9, cell internalization10, receptor clustering11, or effector cell interactions 
(CDC, ADCC)12 underlie the modes of action of most biopharmaceuticals. Functional assays for novel biologics 
are mainly based on mammalian cell culture and individual, time- and cost-intensive activity screening of soluble 
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candidate molecules. Miniaturized microplate-based assay formats can considerably increase the throughput, but 
necessitate more and more complex automation systems for low-volume liquid dispensing and sample analysis13.
Technical progress in the field of microfluidics14 has opened new possibilities for cell-based drug screening. In 
recent years, methodologies in continuous-flow microfluidics for a simultaneous test of compounds on different 
cell types, 3D cell culture on chips for more accurate simulation of tissue structures and physiological conditions, 
and droplet microfluidics for fast generation of millions of individual microreactors with volume in the picolitre 
range, have emerged15. In droplet-based microfluidics, cells and reactants are compartmentalized in small vol-
ume aqueous droplets, utilizing a microfluidic chip with distinct channels for the aqueous phase(s) and for the 
continuous phase - inert carrier fluid (oil)16. This technology opens the door to drug screening on a single-cell 
level, allowing for a drastic increase in throughput and, most importantly, for genotype-phenotype coupling. 
Compartmentalization of individual cells in distinct droplets entraps all secreted molecules and analytes, prevent-
ing interference with other cells and their products17.
As yet, screening of droplets and direct sorting of water-in-oil (w/o) emulsions on custom-made FADS 
(fluorescence-activated droplet sorting) devices18 require sophisticated operation skills. Moreover, FADS devices 
reported to date have relatively low sorting rates and limited variability in fluorescence detection compared to 
commercially available multichannel fluorescence-activated cell sorters (FACS)19. Since commercial FACS devices 
work with aqueous buffers as sheath fluid, the advantages of these instruments over FADS has so far not been fully 
exploited to analyze and process w/o emulsions. One strategy for combining droplet-based compartmentaliza-
tion with FACS is the generation of double emulsions (water-in-oil-in-water or w/o/w), where the primary (w/o) 
emulsion is injected into a hydrophilic microfluidic chip containing an aqueous continuous phase (buffer). This 
procedure results in droplets consisting of an aqueous core surrounded by a thin oil shell, which in turn are dis-
persed in an aqueous solution and has successfully been implemented for the directed evolution of enzymes20–22. 
A drawback of this technique which makes it widely incompatible with mammalian cell-based readouts, is that 
the second emulsification step necessitates the use of detergents for the stabilization of the oil layer23,24. An alter-
native approach to FACS-based sorting of compartmentalized cells lies in the addition of hydrogel-forming 
polymers (agarose, alginate, Matrigel, etc.) to the cell-containing aqueous solution prior to encapsulation. This 
procedure does not impair droplet generation and moreover, retains cell viability and growth since hydrogel 
structures mimic functions of the extracellular matrix. For this reason, cell-laden hydrogel beads have extensively 
been used for the cultivation of mammalian cells in three-dimensional matrices and the generation of multicellu-
lar spheroids25–27. Importantly, it was demonstrated that after hydrogel solidification, microbeads can be readily 
recovered, transferred to an aqueous buffer and further processed by FACS28. The potential of this technique for 
the functional selection of recombinant proteins from variant collections by genotype-phenotype coupling has 
not yet been exploited.
Here we report a novel approach for ultra-high-throughput functional screening and selection of active pro-
tein biologicals based on co-encapsulation of individual S. cerevisiae secretor and mammalian reporter cells in 
agarose-containing microdroplets followed by fluorescence-activated cell sorting (FACS)(Fig. 1). As a model 
experiment, we demonstrate the FACS-based selection of yeast cells secreting functional murine interleukin-3 
(mIL-3) by pairwise co-encapsulation with murine reporter cells which respond to mIL-3 stimulation by expres-
sion of green fluorescent protein (GFP). By two rounds of co-encapsulation and fluorescence activated sorting 
using a standard FACS instrument, mIL-3 secreting yeast cells could be rapidly and efficiently enriched and 
selected from a 1:10,000 dilution with yeast cells expressing an inactive mIL-3 variant.
This generic approach may also be amenable to the functional ultra-high-throughput screening of other bio-
logics beyond cytokines, where a protein variant is displayed or secreted by yeast, while an activity-dependent 
fluorescence readout of live mammalian reporter cells allows for their isolation and identification.
Results
Murine interleukin-3-dependent activation of a reporter cell line. A murine Ba/F3 reporter cell 
line, expressing green fluorescent protein (GFP) upon stimulation with murine interleukin-3 (mIL-3) was con-
structed for a proof-of-concept study. Interleukin-3 is an important regulator of hematopoiesis and supports 
the growth of pluripotent stem cells and progenitors, as well as functional activity of some fully differentiated 
cells29. The responsiveness of the mIL-3-inducible Ba/F3-CIS-d2EGFP reporter cell line in relation to the mIL-3 
concentration was examined and revealed a dose-dependent increase in the GFP fluorescence intensity upon 
stimulation with recombinant mIL-3 with concentrations in the range of 0.01–40 ng/mL (Fig. 2A, black curve). 
Furthermore, flow cytometry analysis confirmed cell population separation of the non-activated (0 ng/mL mIL-
3) and the weakly-activated (0.625 ng/mL mIL-3) reporter cells (Fig. 2B), which is an essential prerequisite for 
efficient positive selection utilizing FACS.
Generation of a non-functional mIL-3 mutant. For verification of the functional screen approach, a 
non-activating mIL-3 variant with minimal sequence alterations (single amino acid substitution) was generated. 
Klein et al. studied in 1997 the receptor-binding site of human IL-3. In this study, one hIL-3 mutant (E22G) 
showed strong (>300 fold) reduction in growth-promoting activity, while retention of relative binding to the 
α receptor subunit of human IL-3 receptor30. Through a structural comparison of the human and murine IL-3 
proteins (Supplementary Fig. S2), we identified the corresponding amino acid position in the mIL-3 ortholog, 
resulting in a non-activating mIL-3 mutant, E49G (Fig. 3C).
Activation of Ba/F3-CIS-d2EGFP reporter cells using mIL-3 containing yeast supernatant. To 
enable detection of agarose microbeads containing an actively secreting yeast cell, a gene construct combining 
mIL-3 and mCherry genes under the control of the same GAL1 promoter was designed (Fig. 3A). Ribosomal 
skipping (T2A peptide) results in the secretion of the mIL-3 protein, carrying a secretion signal (app831) 
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(Supplementary Table S1). Simultaneously, mCherry fluorescent protein accumulates intracellularly in a correla-
tion to the expression rate of the cytokine, as demonstrated by Grzeschik et al.32, and thus serves as an expression 
control.
In order to verify the secretion of functional wt cytokine (mIL-3 wt), Ba/F3-CIS-d2EGFP reporter cells were 
incubated with yeast culture supernatant after yeast induction and cytokine expression for 24 h (Supplementary 
Fig. S3). As a result, reporter cells incubated with the culture supernatant of the mIL-3 wt-secreting yeast exhib-
ited strong GFP fluorescence, while yeast supernatant containing the mutated mIL-3 variant (E49G) induced GFP 
expression levels, comparable to the negative control-reporter cells depleted from mIL-3 (Fig. 3C). Since fluores-
cence levels of the intracellular mCherry expression controls were identical for both mIL-3 variants (Fig. 3B), and 
the discrepancy in the yeast culture densities was negligible, this result indicates successful cytokine secretion and 
Figure 1. Workflow of the high-throughput functional screening procedure: (1) Microfluidic cell co-
encapsulation of yeast secretor cells and mammalian reporter cells. Flow-focusing microfluidic chip with 
two aqueous channels enables the co-encapsulation of the two cell types in monodispersed aqueous droplets. 
Intracellular mCherry fluorescence of the yeast cells and GFP fluorescence of the reporter cells enable analysis 
of the cell distribution in the droplets directly after encapsulation – black arrows indicate droplets containing 
both cell types. (2) Cultivation of the encapsulated cells in emulsion overnight leads to loss/reduction of GFP 
fluorescence in the case of yeast cells secreting non-functional cytokines, while only the droplets containing 
yeast cells secreting biologically active molecules exhibit strong GFP fluorescence. (3) Agarose in the droplets 
is solidified by incubation on ice to form hydrogel microbeads. (4) After emulsion breaking the agarose 
microbeads are transferred to aqueous buffer (PBS). (5) Sorting of double-fluorescent agarose microbeads by 
FACS. (6) Sorted hydrogel microbeads are plated on selective agar for expansion of yeast cells. (7) Yeast clones 
are harvested and screening cycle is repeated.
Figure 2. Reporter cell GFP fluorescence in dependency to the mIL-3 concentration. (A) Mean GFP 
fluorescence determined by flow cytometry after overnight incubation of Ba/F3-CIS-d2EGFP reporter cells in a 
96 well plate with a dilution row (2.5 pg/mL – 41 ng/mL) of recombinant mIL-3 in standard cultivation medium 
(RPMI-1640) or a medium mix (50% RPMI-1640 + 50% DMEM-F12 Ham + 2% w/v galactose). GFP signal 
was normalized to the negative control (reporter cells incubated without mIL-3). (B) Flow cytometry histogram 
of reporter cells activated with different concentrations of rec. mIL-3 obtained on BD Influx cell sorter.
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accumulation in the yeast supernatant and at the same time verifies our assumption, that the single amino acid 
substitution E49G leads to strongly diminished reporter cell activation.
Growth of S. cerevisiae EBY100 in different mammalian culture media. The challenging step 
in the process of establishing a reliable functional screen, which combines two living organisms from distinct 
kingdoms (Fungi and Animalia) is to identify culturing conditions suitable for both species (O2, CO2, humidity, 
medium, temperature, etc.). While S. cerevisiae prefers 30 °C and slightly acidic cell extract-based media33, mam-
malian cell lines need to be cultured by strict conditions – 37 °C, 5% CO2 in defined synthetic media with complex 
composition. In order to address this problem, we examined the yeast cell growth in three standard mammalian 
cell culture media – DMEM, RPMI-1640, and DMEM-F12 Ham. Sufficient cell growth was only observed in the 
DMEM-F12 medium (Fig. 4A), most likely due to the inorganic microelements, contained in the F12 nutrition 
mix. Since the Ba/F3 reporter cells are by standard cultured in RPMI-1640 medium, a 1:1 mixture of RPMI-
1640 + DMEM-F12 Ham was tested, resulting in slightly reduced, but sufficient yeast cell growth and viability. 
Furthermore, the activation of the reporter cells by mIL-3 was not impaired in this medium mix, but stronger 
GFP fluorescence was measured (Fig. 2A, red curve). Reporter cell viability remained over 90% in the mixture 
of both culture media and mCherry fluorescence of the yeast cells upon galactose induction indicated successful 
expression and secretion (Supplementary Fig. S4).
Cocultivation of mIL-3-secreting yeast cells and reporter cells in test tubes. Next, we tested 
the activation of reporter cells in the presence of live cytokine-secreting yeast cells at 37 °C (Fig. 4B) and 30 °C 
(Fig. 4C). Significant GFP signal separation between the Ba/F3 reporter cells, cocultured with the non-activating 
E49G mutant and the wt mIL-3 could be observed at 37 °C. The mIL-3 wt secretion level from the yeast cells was 
sufficient to induce maximal reporter cell activation, which could not be enhanced further by the addition of 
recombinant mIL-3 (Fig. 4B, blue histogram). In contrast, coculturing at 30 °C, resulted in high reporter cell mor-
tality, accompanied by insufficient activation of the mammalian cells, even after stimulation with recombinant 
mIL-3 (Fig. 4C, blue histogram).
Microfluidic co-encapsulation of yeast secretor cells and mammalian reporter cells in 
agarose-containing droplets. Utilizing a microfluidic system, we were able to co-encapsulate 
cytokine-secreting yeast cells together with mammalian reporter cells in monodispersed and homogenous 
agarose-containing droplets (Fig. 1). The droplet size is determined by the channel size of the microfluidic chip, as 
Figure 3. Analysis of mIL-3-secretion from S. cerevisiae cells. (A) Gene construct for the expression and 
secretion of mIL-3 in S. cerevisiae. Galactose-induced transcription (GAL1 promoter) leads to generation 
of a single mRNA transcript comprised of the transcripts of mIL-3 and a red fluorescent protein (mCherry). 
Ribosomal skipping peptide (T2A) between the two genes facilitates the translation of two separate proteins: 
mIL-3 with N-terminal secretion signal (app8) is secreted in the culture medium, while mCherry remains 
trapped intracellularly and serves as an expression control. (B) Mean mCherry fluorescence of yeast cells 
before and after induction with galactose. (C) Flow cytometry histogram of Ba/F3-CIS-d2EGFP reporter cells 
incubated with yeast supernatant after expression and secretion of mIL-3 wt or mIL-3 E49G for 24 h at 30 °C. As 
positive and negative controls, reporter cells were cultured in standard (RPMI-1640) medium with 10 ng/mL 
rec. mIL-3 or without mIL-3, respectively.
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well as by the flow rates of the aqueous and oil phases. Using a commercially available flow-focusing microfluidic 
chip with 50 µm etch depth and flow rates of 4 µL/min and 35 µL/min for the aqueous and oil phases, respectively, 
droplets with 44 µm diameter on average and about 45 pL volume were generated (Supplementary Fig. S8A).
Cell distribution in the droplets is dependent on the cell density of the encapsulated suspension and on the 
droplet size and can be predicted by Poisson’s equation34. Thus, optimal occupancy (one yeast and one mamma-
lian cell) occurs only in a fraction of all droplets, affecting directly the FACS selection. In case low cell density of 
both cell types is used for co-encapsulation, the co-encapsulation efficiency drops drastically, resulting in a very 
high number of useless droplets. On the other side, high cell density leads to encapsulation of multiple yeast/
mammalian cells in one droplet, and sorting of multiple yeast clones based on mammalian response induced by a 
single yeast cell (false positive). However, during subsequent co-encapsulation and selection cycles, the enriched 
false-positive yeast cells are eliminated to a large extend. Since our functional screen approach enables multiple 
screening rounds for specific enrichment of activating variants, more than one yeast cell per droplet is tolerated. 
Cell densities of 4 × 107 yeast cells/mL and 2 × 107 mammalian cells/mL were used for co-encapsulation, corre-
sponding to an average of 0.9 yeast and 0.45 mammalian cells/droplet according to Poisson distribution. In order 
to determine the actual distribution of cells in the droplets, co-encapsulated cells in w/o emulsion were analyzed 
microscopically (Fig. 5, 0 h). While about 55% of all droplets were empty, approx. 23% of the occupied droplets 
contained one yeast and 50% one mammalian cell (Supplementary Fig. S8B). Generally, yeast cells are prone to 
flocculation35, which reflects the higher number of droplets with more than one yeast cell (38%) in comparison 
to the fraction of droplets with more than one mammalian cell (19%). Based on the microscopical analysis of 226 
droplets, an average of 0.6 yeast and 0.41 mammalian cells per droplet were estimated, resulting in a theoretical 
co-encapsulation probability of about 15%. On account that only about 70% of the yeast cells exhibited sufficient 
mCherry fluorescence, the fraction of droplets containing an actively secreting yeast cell and a viable mammalian 
cell was determined by flow cytometry to be in the range between 8% and 10% of all droplets (Supplementary 
Fig. S5A). Furthermore, since nutrition and space are limited inside the picovolume droplets, co-encapsulation 
of a yeast cell with multiple mammalian cells could lead to false negative signals, due to reduced viability of the 
mammalian cells during the incubation step. To avoid losing desired variants due to false negative events, over-
sampling the yeast diversity during the co-encapsulation step at least 100 times is necessary. Nevertheless, with 
a generation speed of about 8 × 106 droplets/h, at least 8 × 105 yeast cells could be successfully co-encapsulated 
with a mammalian reporter cell in just one hour, making this system feasible for the screening of yeast-based 
libraries.
Activation of reporter cells by co-encapsulation with mIL-3 secreting yeast cells in agarose 
droplets. Murine Ba/F3 cells are generally mIL-3 dependent for cell growth. For this reason, the reporter 
cells were propagated with mIL-3-containing culture medium (10 ng/mL), leading to active GFP expression prior 
to co-encapsulation. This enabled the microscopically and flow cytometrical observation of the cell distribution 
Figure 4. Investigation of optimal cocultivation conditions. (A) Growth curve of S. cerevisiae EBY100 in 
different mammalian culture media. Cell density was measured photometrically every hour for 10 h. (B) 
Cocultivation of Ba/F3-CIS-d2EGFP reporter cells with viable yeast cells in medium mix (50% RPMI-
1640 + 50% DMEM-F12-Ham + 2% w/v galactose) at 37 °C (B) or 30 °C (C). Flow cytometry histograms depict 
the GFP fluorescence signal of the reporter cells only.
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directly after encapsulation as shown in Fig. 5 and Supplementary Fig. S5A. Directly after co-encapsulation with 
mIL-3 wt-, or mIL-3 E49G-secreting yeast cells, the mammalian cells in both samples showed strong GFP fluo-
rescence, while no fluorescence background in the droplets could be observed (Fig. 5, 0 h). After incubation of 
the droplet-w/o-emulsion overnight at 37 °C, the droplets containing the non-functional mIL-3 variant exhibited 
diffuse fluorescence, spread throughout the whole droplet, implying cell lysis and release of the remaining GFP in 
the droplet (Fig. 5A, 18 h). In the case of the activating mIL-3 wt-secreting yeast, significantly more mammalian 
cells appear intact, leading to mainly cell-concentrated GFP fluorescence with higher intensity when yeast cells 
are colocalized in the droplet (Fig. 5B, 18 h). These observations were confirmed by flow cytometry analysis of the 
solidified agarose microbeads (Fig. 6). While the mCherry fluorescence intensity of both samples remains iden-
tical, indicating the same cytokine expression levels (Fig. 6B), the GFP fluorescence in case of co-encapsulation 
with wt mIL-3 is significantly stronger (Fig. 6C). By comparison of the GFP intensity of the double-fluorescent 
agarose microdroplets, the mIL-3 wt-containing microbeads exhibited noticeably stronger GFP fluorescence 
(Fig. 6D) with 1% lying in the high-stringency sorting gate (Fig. 6A P2-Q2). These results indicate sufficient 
viability and functionality of the mammalian reporter cells co-cultivated with the yeast cells under the tested 
conditions. Furthermore, a cell viability analysis of the encapsulated cells after co-cultivation of reporter and yeast 
cells in emulsion, confirmed no dramatic increase of mammalian cell mortality, with 60–70% viable reporter cells 
during FACS processing (Supplementary Fig. S5B).
Enrichment of reporter-activating yeast after FACS of 1:10,000 mixture of mIL-3 wt and mIL-3 
E49G. Gel microdroplet-fluorescence activated cell sorting (GMD-FACS) of S. cerevisiae was first described 
in 1995 as a tool to isolate slowly growing yeast cells from a mixed population36. Since particle size plays a decisive 
role in the sorting process, we first investigated the sorting efficiency using our agarose microbeads. To this end, 
GFP-producing EBY100 yeast cells were mixed with an excess of mCherry-producing EBY100 yeast cells and 
were encapsulated in agarose-containing microdroplets. GFP-positive agarose microbeads were sorted using a 
200 µm nozzle (capable of sorting particles ≤ 50 µm). Flow cytometry after the expansion of the sorted yeasts 
revealed predominantly GFP-fluorescent yeast cells (Supplementary Fig. S1), confirming a highly efficient sorting 
process of the agarose microbeads, generated according to our encapsulation and sorting protocol.
In order to demonstrate the applicability of our system for a mammalian-based functional screen, we mixed 
the mIL-3 wt-secreting yeast cells with the yeast cells secreting the non-functional E49G mutant at a 1 to 10,000 
ratio. Co-encapsulation with Ba/F3 reporter cells was performed as described above and only double-fluorescent 
agarose microbeads with strong GFP fluorescence were sorted (Supplementary Fig. S6). A reporter cell activa-
tion assay with culture supernatant of the bulk yeast populations revealed gradual enrichment of “activating 
yeast” (mIL-3 wt secretor) after the first and second sorting rounds (Fig. 7A), also confirmed by next-generation 
sequencing (Fig. 7C). PCR analysis of single clones after round 2 of encapsulation and FACS identified 9 of 54 
clones as mIL3 wt (Supplementary Fig. S7) and supernatants from all of those clones induced reporter cell activa-
tion (Fig. 7B), confirming significant enrichment of wt mIL-3-secreting yeast from 0.01% to about 17%.
In order to determine the degree of enrichment reached by our functional selection approach, mixing exper-
iments with 1:10, 1:100, and 1:1,000 ratios of both yeast types were additionally performed. Mixtures with 1:10 
Figure 5. Microscopical analysis of co-encapsulated reporter and yeast cells. Ba/F3-CIS-d2EGFP were 
co-encapsulated with mIL-3 E49G (A) and mIL-3 wt (B) yeast cells in agarose-containing droplets and 
microscopically observed as w/o emulsion 0 h and 18 h after co-encapsulation. Black arrows indicate droplets 
were yeast and mammalian cells are localized in the same droplet.
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and 1:100 wildtype to mutant (E49G) mIL-3 demonstrated rapid enrichment of wt mIL-3 after a single func-
tional selection cycle (Supplementary Fig. S10A). The 1:1,000 mixture was subjected to two consecutive selec-
tion rounds, resulting in gradual enrichment of the wildtype cytokine to about 26% of the population after R2 
(Supplementary Fig. S10B,C). Enrichment degree in all experiments was limited to 15–26%. However, this is 
compatible with most screening campaigns since sufficient number of functionally active single clones could eas-
ily be identified by single clone analysis. If necessary, further increase in the enrichment degree could be achieved 
by decreasing the yeast cell density used for the co-encapsulation process. This would minimize encapsulation of 
multiple yeast cells in the same droplet and thus, sorting of false positive yeast cells would be avoided.
Discussion
With the rapid expansion of the biopharmaceutical market, the demand for straightforward, cost-effective and 
time-saving discovery technologies for the generation of potent functional biologics has increased tremendously. 
The interest in the establishment of novel high-throughput functional screening methods, which surpass the 
limitations of the current state of the art technologies has raised, leading to the development of commercial plat-
forms like Cyto-Mine from SphereFluidics37, Beacon Optofluidic Platform from Berkeley Light, and xPloration 
Screening Platform from xCella Biosciences38. With the advantages of sample miniaturization and encapsulation 
in distinct microdroplets, microfluidic-assisted screening has emerged as a promising next-generation approach.
Here we demonstrate a novel strategy for mammalian reporter cell-based functional screening by 
co-encapsulation of viable mammalian reporter cells with yeast secretor cells in millions of agarose-containing 
microdroplets. Our system is compatible with ultra-high-throughput screening utilizing a commercially avail-
able FACS device without need of extensive optimization and adaptation. With the help of a proof-of-principle 
activator-reporter system, we demonstrate the feasibility of the system for functional screening of protein variants 
produced by yeast. S. cerevisiae as a library host combines the advantages of a microbial expression system, which 
is characterized by high transformation efficiencies and fast growth with those of eukaryotes since they possess 
an unfolded protein response machinery for elimination of misfolded proteins prior to secretion39. In addition, 
it is compatible with both immune and combinatorial libraries40,41. Simultaneous secretion and display of the 
library variants on the yeast surface could be achieved by utilizing an inefficient ribosomal skipping (F2A)42, 
enabling alternating affinity-based43 and functional selection using the same mammalian target (reporter) cell 
Figure 6. Flow cytometry of reporter cells co-encapsulated with mIL-3 E49G and mIL-3 wt yeast cells in 
agarose microbeads after 18 h of incubation at 37 °C. (A) Two dimensional FACS plot: x-axis represents GFP 
fluorescence of reporter cells (530/40[488] laser) and y-axis depicts the mCherry fluorescence of yeast cells 
(593/40 [561] laser). Gating strategy (blue) represents the double-fluorescent hydrogel microbeads identified 
as positive events during sorting (P2-Q2). (B) Overlay of the mCherry fluorescence signals of both samples. 
(C) Overlay of the GFP fluorescence signals of both samples. (D) Overlay of the GFP fluorescence intensity 
of the agarose microbeads containing mammalian and yeast cells (black box) from both samples. (E) Two-
dimensional overlay of both samples (generated with FlowJo).
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line. Furthermore, human-like N-glycosylation could successfully be engineered in S. cerevisiae44, which is an 
important factor influencing the bioactivity, physicochemical properties, and pharmacokinetics of the majority 
of biologics45–47. Lastly, S. cerevisiae is a robust organism, capable of fast expansion after encapsulation and sorting 
of agarose microbeads, which enables functional screening in multiple rounds or different setups without risk of 
losing desired candidates due to low cell viability.
In comparison, several similar screening approaches have been published in recent years, which once again 
emphasizes the high demand in this field. In 2017, Fang et al. proposed an affinity-based antibody screening 
platform, based on co-encapsulation of antibody-secreting Pichia pastoris and fixed mammalian target cells in 
agarose microdroplets48. This study demonstrated that GMD-FACS is a reliable selection method and classical 
antibody staining procedures can be applied for the specific fluorescent detection of target-bound antibodies in 
the agarose microbeads. However, since this procedure was not optimized for viable mammalian cells, functional 
antibody screening would not be feasible. Nevertheless, we acknowledge the potential of utilizing P. pastoris for 
efficient secretion of full-length IgG antibodies49 and we are confident that our functional screening system could 
easily be adapted for co-encapsulation with antibody-secreting P. pastoris.
Another system for microfluidic-based functional antibody selection was introduced by Zheng et al. in 
2018. In this study, the authors co-encapsulated phage-secreting E. coli and mammalian reporter cells in 
Figure 7. Analysis of selection outcome after functional selection of a 1:10,000 mixture of mIL-3 wt- and mIL-3 
E49G-secreting yeast. (A) Mean GFP fluorescence signals of reporter cells after incubation with yeast culture 
supernatants of the induced population of the 1 to 10,000 mix of mIL-3 wt and mIL-3 E49G yeast cells and the 
populations after sorting round 1 and 2 (green). As controls (grey) reporter cells were cultivated with yeast 
supernatants of the non-functional E49G mutant, the biologically active mIL-3 wt, and 50 ng/mL recombinant 
mIL-3. All yeast cultures were inoculated at the same cell density and were cultured for 24 h at 30 °C. Final cell 
density was measured and the volume of yeast supernatant added to the mammalian cells was normalized to the 
final cell density. Statistical significance analysis was performed by One-way ANOVA and Turkey HSD post-
hoc test (Supplementary Table S4). Relevant statistical significance between samples was marked on the graph. 
(B) Activation of reporter cells by incubation with culture supernatants of single yeast clones after the second 
round functional screening of the 1 to 10,000 mix. Single clones identified as mIL-3 wt by PCR are marked 
with an asterisk. All results represent the averaged mean fluorescence intensity from 3 biological replicates. 
Statistical analysis was performed by One-way ANOVA and Dunnett’s post-hoc multiple comparison test 
(Supplementary Table S5). Statistical significance between the reporter activation levels of the single clones and 
the negative control (mIL-3 E49G) was marked on the graph. (C) Fold enrichment of mIL-3 wt NGS reads in 
the populations of the first and second rounds of functional screening of the 1 to 10,000 mixture of mIL-3 wt- 
and mIL-3 E49G-secreting yeast.
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medium-containing aqueous droplets and were able to detect reporter cell activation by agonist antibody frag-
ment (scFv) presented on the phage surface50. This work expands the compatibility of droplet-based functional 
screening towards one of the best-established screening approaches, phage display51. We are convinced that in 
combination with a straightforward ultra-high-throughput GMD-FACS (by addition of agarose to the encapsu-
lation medium) this approach would be feasible for phage display-based selection of agonistic antibody variants, 
bypassing the need of double emulsion generation, addressed by the authors.
A further example, demonstrating the versatility of droplet-based functional screening utilizing mammalian 
reporter cells is the study of Yaginuma et al. (2019). In a similar to our system fashion, they co-encapsulated 
peptide-secreting S. cerevisiae with mammalian reporter cells, responding to activation of the G-protein cou-
pled receptor hGLP1R52. The fluorescence read-out, in this case, was achieved by expression and secretion of 
β-galactosidase (LacZ) as a reporter enzyme, which converts a non-fluorogenic substrate, added to the droplets, 
into a fluorescent molecule. Selection of agonistic peptide variants from a randomized peptide library was per-
formed by co-encapsulation of the peptide-secreting yeast with the reporter cells and manual microscopical obser-
vation of the droplets, followed by isolation of the highly fluorescent droplets by a micromanipulator. This study 
illustrates the applicability of droplet-based cocultivation screens utilizing viable mammalian cells for addressing 
challenging targets as GPCRs, where the generation of reliable soluble protein for standard affinity-based screens 
is not trivial. However, the throughput of this system is mainly limited by the microscope-assisted isolation of 
fluorescent droplets.
In summary, a murine Ba/F3 reporter cell line, expressing green fluorescent protein (GFP) upon stimula-
tion with murine interleukin-3 (mIL-3) was constructed for a proof-of-concept study. Co-encapsulation of wt 
mIL-3 secreting yeast cells with Ba/F3 reporter cells in agarose-containing droplets resulted in strong activation 
of the reporter cells, whereas after co-encapsulation with a non-functional mutant only moderate GFP signal 
was detectable. Co-encapsulating a 1 to 10,000 mixture of wt mIL-3 and the mutant secreting yeast cells with 
the mammalian reporter cell line and sorting for double-fluorescent events resulted in rapid enrichment of yeast 
cells secreting biologically active wt mIL-3 molecules. In conclusion, we believe that our novel platform for an 
ultra-high-throughput functional screening could enable and accelerate the discovery of new functional biolog-
ics, including cytokines, agonistic or internalizing antibodies, and soluble receptors53.
Materials and methods
Generation of the mammalian reporter cell line - Ba/F3-CIS-d2EGFP. The coding sequence 
for d2EGFP (destabilized enhanced Green Fluorescent Protein) was amplified by polymerase chain reac-
tion from plasmid pd2EGFP-N1 (Takara Bio, formerly Clontech, Mountain View, CA, USA) using primers 
JB46F1 (5′-CGAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCACCATGGTGAGCA-3′) and JB47R1 
(5′- ACGGATCCCTTAAGATACATTGATGAG-3′). PCR amplicon was digested with HindIII and BamHI and 
cloned into plasmid pGL4.17 (Promega, Madison, WI, USA) after removal of the luciferase gene by excision with 
HindIII and BamHI.
The resulting construct pGL4.17-d2EGFP was subsequently subjected to a partial digest with KpnI and HindIII 
to allow for the cloning of a fragment containing the regulatory promoter region from the STAT5-responsive 
human CIS gene. The CIS promoter fragment was excised from reporter gene plasmid pGV-CIS-luc54, kindly 
provided by Dr. A. Yoshimura, Kyushu University, Fukuoka, Japan) using KpnI and HindIII and placed upstream 
of the d2EGFP coding sequence to yield pGL4.17-CIS-d2EGFP.
Plasmid pGL4.17-CIS-d2EGFP was introduced into the interleukin-3-dependent murine pro-B cell line Ba/
F3 by electroporation as described previously55. Neomycin-resistant cell clones were selected by cultivation in the 
presence of 1 mg/mL G418 for two weeks. Obtained G418-resistant cell clones were tested for mIL-3-inducible 
d2EGFP expression by 3 h cytokine starvation of 105 cells in 100 µL aliquots followed by stimulation for 12 h 
with 10 ng/mL recombinant murine interleukin-3 (rec. mIL-3) (Invigate GmbH, Jena, Germany). Inducible 
EGFP expression was analyzed by flow cytometry employing a CyFlow Space device (Sysmex Partec GmbH, 
Görlitz, Germany) and the software Cyflogic 1.2.1 (http://www.cyflogic.com), resulting in the identification of 
the mIL-3-responsive reporter cell line Ba/F3-CIS-d2EGFP.
Reporter cells were further cultured in RPMI-1640 medium supplemented with 10% FBS and 1% 
Penicillin-Streptomycin solution (Pen/Strep) (Sigma Aldrich P4333), 10 ng/mL recombinant mIL-3 were added 
to the medium for normal culturing and expansion of the cells.
Responsiveness of the Ba/F3-CIS-d2EGFP reporter cells to mIL-3 was examined using a dilution row of 
recombinant mIL-3. Therefore, 105 reporter cells/well were washed twice with PBS, resuspended in 100 µL/sample 
culture medium with 10% FBS and 1% Pen/Strep and plated in a 96-well plate. Recombinant mIL-3 was serially 
diluted (1:2) in the same culture medium (0.005–82 ng/mL) in a volume of 100 µL/sample. The mIL-3-containing 
medium was added to the cell suspension in triplicates and the cells were incubated in a humidified atmosphere 
at 37 °C, 5% CO2 overnight (18–20 h). Mean GFP fluorescence of the population was measured on BD Accuri C6 
flow cytometer and cell populations of some concentrations were additionally analyzed on BD Influx Cell Sorter.
Yeast strains, media and reagents. Saccharomyces cerevisiae strain EBY100 [MATa URA3-52 trp1 
leu2Δ1 his3Δ200 pep4:HIS3 prb1Δ1.6 R can1 GAL (pIU211:URA3)] (Thermo Fisher Scientific) was utilized for 
the secretion of murine IL-3. SD (synthetic dropout) medium was composed of 8.6 g/L NaH2PO4 × H2O, 5.4 g/L 
Na2HPO4, 1.7 g/L yeast nitrogen base without amino acids, 5 g/L ammonium sulphate, 1.3 g/L dropout amino 
acids mix (w/o leucine) and 20 g/L dextrose. SG medium was prepared identically except for the substitution 
of dextrose sugar with galactose. Phosphate-buffered saline (PBS) contained 8.1 g/L NaCl, 1.13 g/L Na2HPO4, 
0.75 g/L KCl, and 0.27 g/L KH2PO4.
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Generation of mIL-3-secreting yeast. For the generation of S. cerevisiae-secretion vector a pYD1 plas-
mid (Yeast Display Vector Kit, version D, #V835-01, Thermo Fisher Scientific), comprising GAL1-promoter, Leu2 
(Beta-isopropyl malate dehydrogenase), and ampicillin resistance was used. mIL-3 gene was amplified by PCR 
and complementary overhangs (30–40 bp) were introduced for gap repair cloning procedure. Gene sequence of 
mCherry fluorescent protein with T2A ribosomal skipping peptide on the 5´-end was generated by PCR and 
complementary overhangs were introduced. Secretion vector comprising constructs in the following order: 
GAL1-promoter, app8-secretion signal, mIL-3 wt gene, T2A ribosomal skipping peptide and mCherry fluores-
cent protein (Fig. 3A) was generated in single-step gap-repair cloning in S. cerevisiae EBY100.
A non-functional mIL-3 variant (E49G) was generated identically using corresponding mismatch primers for 
the PCR on the wt mIL-3 gene.
For gap repair cloning EBY100 yeast cells were prepared according to Benatuil and colleagues56. 
pYD-Leu-TRAP vector (Supplementary Fig. S9) was digested with NdeI and PmeI and the linearized backbone 
was extracted from an agarose gel using Wizard SV Gel and PCR Clean-Up System (Promega). For gap repair 
cloning,1 µg purified backbone was mixed with 300 ng mIL-3 insert and 500 ng T2A-mCherry insert. 100 µL elec-
trocompetent EBY100 cells were added to the DNA and incubated for 10 min on ice. Cells were electroporated 
using BioRad electroporation system, according to the protocol of Bernatuil et al. and incubated for 1–2 h in 
2–3 mL YPD medium (20 g/L dextrose, 20 g/L tryptone and 10 g/L yeast extract) at 30 °C and 180 rpm. Cells were 
pelleted by centrifugation at 4000 rpm for 3 min and washed once with sterile PBS. Finally, the cells were plated on 
selective minimal medium agar plates and incubated for 2–3 days in a static incubator at 30 °C.
Verification of mIL-3 secretion and activation of reporter cells. For the verification of successful 
secretion of active (wt) and inactive (E49G) mIL-3, the corresponding yeast clones were inoculated in an autoin-
duction medium (25% SD + 75% SG) and cultured at 30 °C, 180 rpm for 48 h. Yeast supernatant was harvested by 
centrifugation for 10–15 min at 17 000 × g and sterile filtered using a 0.2 µm sterile filter. The pH of the superna-
tant was measured and neutralized using 1 M HEPES buffer. 1 × 105 reporter cells/sample (Ba/F3-CIS-d2EGFP) 
were harvested and washed 2 times with 5 mL sterile PBS to remove bound recombinant mIL-3. The cells were 
resuspended in 100 µL/sample RPMI-1640 + 20% FBS and 1% Pen/Strep solution and plated in a 96 well plate. 
100 µL yeast supernatant were added to each well and the cells were incubated at 37 °C in a humidified atmos-
phere with 5% CO2 for 18–20 h. GFP fluorescence intensity was measured on the next day using flow cytometry.
Growth and induction of yeast cells in mammalian medium. Yeast cells (S. cerevisiae EBY100 
or EBY100-mIL-3 wt) were inoculated at a cell density of 5 × 106 cells/mL (OD600 = 0.5) in 3 mL mammalian 
medium (DMEM high glucose, RPMI-1640, DMEM-F12 Ham, or mix of 50% RPMI-1640 + 50% DMEM-F12 
Ham) and cultivated at 30 °C or 37 °C, 180 rpm. OD600 was measured every 60 min.
Yeast induction (EBY100-mIL-3 wt) was determined by measuring the fluorescence intensity of the intracel-
lular expression marker (mCherry) by flow cytometry after 24 h of cultivation in the corresponding mammalian 
medium, supplemented with 2% galactose. The percentage of mCherry-fluorescent cells was used as a measure 
of yeast induction.
Cocultivation of mammalian reporter cells and mIL-3-secreting yeast in medium. Yeast cells, 
secreting wt mIL-3 or E49G mIL-3 were expanded and induced overnight in autoinduction medium (25% 
SD + 75% SG). 1 × 107 yeast cells were mixed with 1 × 106 Ba/F3-CIS-d2EGFP reporter cells in 1 mL mam-
malian medium mix (50% RPMI-1640 + 50% DMEM-F12 Ham), supplemented with 10% FBS, 2% galactose 
and 1% Pen/Strep and transferred in a 50 mL centrifugation tube. The vessels were sealed with a gas-permeable 
membrane (VWR 60941-084) in order to prevent evaporation of the medium. Cells were cocultured overnight at 
37 °C, 110 rpm in a humidified atmosphere with 8% CO2 or at 30 °C, 180 rpm. Activation of the reporter cells was 
estimated based on the GFP fluorescence measured on BD Influx cell sorter.
Single-cell co-encapsulation using droplet microfluidics. For the encapsulation in 
hydrogel-microdroplets, fresh encapsulation medium was prepared each time: 3% w/v ultra-low gelling temper-
ature agarose (Sigma Aldrich A5030) was suspended in 2 mL mammalian medium mix (50% RPMI-1640 + 50% 
DMEM-F12 Ham) and the suspension was heated up in a microwave until the agarose completely dissolved. The 
agarose solution (3% w/v) was then tempered in a water bath at 37 °C. All other components of the encapsulation 
medium were tempered at 37 °C, as well, to prevent solidification of the agarose. Encapsulation medium consisted 
of 0.75% agarose, 20% FBS, 20% Opti-Prep density gradient medium (Sigma Aldrich D1556), 2% galactose and 
1% Pen/Strep in medium mix (50% RPMI-1640 + 50% DMEM-F12 Ham) (Supplementary Table S3).
Cytokine-secreting yeast cells (wt mIL-3 or E49G mIL-3) were propagated and simultaneous expression 
induction was achieved utilizing selective autoinduction medium (25% SD + 75% SG) at 30 °C, 180 rpm. Cell 
density was estimated using a photometer (OD600 = 1 corresponds to 1 × 107 yeast cells/mL) and 4 × 107 yeast 
cells were pelleted and washed once with sterile PBS. Cells were resuspended in 1 mL of encapsulation medium 
and kept at 37 °C during the whole encapsulation process to prevent agarose solidification.
Ba/F3-CIS-d2EGFP reporter cells were cultivated as described above. Cell density and viability was estimated 
using TC20™ Automated Cell Counter (Bio-Rad) and Trypan Blue stain. 2 × 107 viable cells were harvested by 
centrifugation at 800 rpm for 5 min at room temperature and washed twice with sterile PBS. Cells were resus-
pended in 1 mL encapsulation medium and kept at 37 °C as well.
Co-encapsulation was performed with a µEncapsulator system (Dolomite Bio) using a 50 µm fluorophilic 
2 Reagent Droplet Chip (Dolomite Bio 3200445). 3 M™Novec™7000 engineered fluid, supplemented with 2% 
Pico-Surf surfactant (Sphere Fluidics) was used as a continuous phase. Prior to cell encapsulation, the micro-
fluidic system was equilibrated to 37.5 °C using the integrated TCU device to prevent clogging of the chip by 
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solidified agarose. 100 µL of the yeast cells, resuspended in agarose-containing encapsulation medium were 
applied on the µEncapsulator Sample Reservoir Chip (Dolomite Bio 3200444) and 100 µL of the reporter cells 
were applied on the second aqueous channel. Co-encapsulation was performed at flow rates of 3–4 µL/min for 
both cell suspensions and 30–40 µL/min for the continuous phase, thus resulting in encapsulation rates of 1.4 × 
105 yeast cells and 7 × 104 reporter cells per minute. As a running fluid for the pressure pumps of the aqueous 
channels, plain 3 M Novec 7000 engineered fluid (without surfactant) was used. The generated droplets were 
collected in sterile 1.5 mL tubes (also tempered at 37 °C all the time).
After the cell samples (100 µL each cell type) were completely encapsulated and no droplet formation could 
be observed, the microfluidic system was paused and the emulsion was transferred to a rotating incubator and 
incubated for 17–18 h at 37 °C, 110 rpm, in a humidified atmosphere and 8% CO2.
Mixing Experiments using wt mIL-3- and E49G mIL-3-secreting yeast. To demonstrate that our 
platform is suitable for selection based on the functionality of the secreted molecules, mixing experiments with 
the biologically active and inactive mIL-3-variants were performed. To this end, yeast cells secreting the active wt 
mIL-3 were mixed to a 1:10,000 ratio with the yeast which secretes nonfunctional mIL-3 E49G mutant. Yeast cells 
were expanded and pre-induced separately and after cell density determination mixed in the corresponding ratio. 
Co-encapsulation with the reporter cells was performed as described above.
For the 1:10,000 proof-of-concept approach, 3.2 × 107 yeast cells were co-encapsulated with 1.6 × 107 reporter 
cells and incubated overnight.
Agarose bead isolation and fAcS sorting. Prior to analysis and sorting, the emulsion with the 
co-encapsulated cells was cooled for 15–20 min on ice in order to allow the agarose to solidify. The clear oil phase 
under the emulsion was removed and the emulsion was broken using 150 µL PFO (1H,1H,2H,2H-perfluoro-
1-octanol Sigma Aldrich). After short centrifugation (100 rpm, 10 s), the agarose microbeads were visible as a 
clear, yellow upper phase. The lower phase, containing the PFO and the residual fluorocarbon oil, was removed 
and the agarose beads were resuspended carefully in 1 mL sterile, cold PBS. Prior to FACS, the resuspended aga-
rose beads were filtered using a 70 µm cell strainer to prevent clogging of the sample line or nozzle.
Sorting of agarose beads was performed on BD Influx cell sorter, equipped with a 200-micron nozzle tip (BD 
Biosciences), with a 6 kHz drop frequency. BD FACSFlow sheath fluid (Fisher Scientific) was used with 3.0 psi 
sheath pressure.
After each sorting round, the sorted yeast-containing agarose beads were plated on selective SD agar plates 
and incubated for 3 days at 30 °C in a static incubator. The colonies were harvested from the plates using sterile 
SD and stored at 4 °C until further usage.
enrichment analysis using bulk populations after each sorting round. Monitoring of sorting effi-
ciency was performed using bulk populations after each sorting round. To this end, yeast cells of the non-sorted 
mix and of the corresponding sorting rounds were inoculated at a cell density of 1 × 107 cells/mL in test tubes 
containing 2 mL of DMEM-F12 Ham medium, supplemented with 2% galactose and 1% Pen/Strep. Cells were 
cultivated for 24–48 h at 30 °C, 180 rpm and after cell density measurement, the yeast cultures were centrifuged 
for 15 min, 17 000 × rcf in 1.5 mL Eppendorf tubes. The supernatant (1 mL) was transferred to a new tube and pH 
was neutralized with 100 µL 1 M HEPES buffer. 1 × 105 reporter cells/sample were harvested and washed twice 
with sterile PBS. Reporter cells were resuspended in 100 µL RPMI medium, supplemented with 20% FBS and 
1% Pen/Strep. The volume of yeast supernatant (max. 100 µL), added to the reporter cells, was normalized to the 
final cell density of the yeast culture. Reporter cells were subsequently incubated overnight (15–18 h) at 37 °C, 5% 
CO2 in a 96 well plate. Enrichment of functional wt mIL-3-secreting yeast cells was verified by the measurement 
of elevated GFP-fluorescence signal, normalized to background fluorescence of non-activated Ba/F3 reporter 
cells. GFP fluorescence signal (10,000 viable cells/sample) was determined using BD Accuri C6 flow cytometer. 
Statistical analysis was performed by One-way ANOVA followed by Honestly Significant Difference test (Tukey 
HSD post-hoc) with the help of GraphPad Prism software. GFP signals of all samples were statistically compared 
and the statistical significance (P value) was determined (Supplementary Table S4).
PCR screen of single clones from mixing experiments. For facile analysis of the sorting process in 
case of mixed mIL3 wt and E49G, a mIL-3 wt- specific primer was designed (Table S2). Colony PCR with single 
clones after the second sorting round was performed, where a 400 bp PCR product indicated the presence of wt 
mIL-3 coding DNA sequence. For the colony PCR, each colony was resuspended in 50 µL 20 mM NaOH and was 
heated at 98 °C for 15 min in 200 µL PCR tubes. After cooling down, the samples were centrifuged to pellet the cell 
debris and 1 µL supernatant per clone was used as a template. PCR was performed utilizing Taq DNA Polymerase 
(Qiagen) according to the standard manufacturer’s protocol. PCR consisted of initial denaturation step (94 °C 
- 3 min); 30 cycles of denaturation (94 °C – 30 s), annealing (60 °C – 30 s), and elongation (72 °C – 30 s); final 
elongation (72 °C – 5 min). Colony PCR was analyzed using agarose gel electrophoresis.
Positive single yeast clones were further analyzed by means of reporter cell activation assay using supernatants 
of each single clone as described above. Mean GFP fluorescence was determined using BD Accuri C6 flow cytom-
eter and was normalized to background fluorescence of non-activated Ba/F3 reporter cells. Statistical analysis was 
performed by One-way ANOVA followed by Dunnett’s test for multiple comparison of the single clones with the 
negative control (mIL-3 E49G). The statistical significance (P value) was estimated using the indicated methods 
in GraphPad Prism software (Supplementary Table S5).
Next-Generation Sequencing (NGS). The efficiency of our functional screening approach was analyzed 
using NGS of the mixed 1:10,000 mIL-3 wt and mIL3-E49 yeast population, as well as of the bulk populations 
after each selection round. To this end, yeast cell populations were propagated for 24 h at 37 °C in SD medium. 1 
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× 108 cells were centrifuged and plasmid preparation was performed using Zymoprep Yeast Plasmid Miniprep Kit 
(Zymo Research) according to the manufacturer’s protocol. Specific oligonucleotides, comprising partial Illumina 
adapters and a DNA barcode were designed (Supplementary Table S2). PCR was performed using 0.5 µL plasmid 
preparation from each population as a template utilizing Q5 Polymerase (NEB) according to the standard proto-
col (NEB). PCR amplicons were purified using Wizard SV Gel and PCR Clean-Up System (Promega) following 
the manufacturer’s protocol. Samples were sent for NGS to GENEWIZ (Leipzig, Germany) and sequencing data 
analysis was performed using Geneiuos 2020.1.
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